Advertisement

Pathology & Oncology Research

, Volume 24, Issue 3, pp 533–540 | Cite as

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

  • Paulo Roberto Stevanato FilhoEmail author
  • Samuel Aguiar Júnior
  • Maria Dirlei Begnami
  • Fábio de Oliveira Ferreira
  • Wilson Toshihiko Nakagawa
  • Ranyell Matheus Sobreira Batista Spencer
  • Tiago Santoro Bezerra
  • Philip Edward Boggiss
  • Ademar Lopes
Original Article

Abstract

The incidence of colorectal cancer (CRC) is lower in women than in men, and sex steroids can be considered contributing factors because oral contraception usage and estrogen replacement therapy are associated with decreased risk. Conversely, colorectal polyp development in familial adenomatous polyposis (FAP) begins during puberty. The objectives were to evaluate the relationship between the expression of these hormone receptors and adenoma-carcinoma progression, CRC stage and overall survival. We studied 120 A.C. Camargo Cancer Center patients diagnosed with either FAP-associated or spontaneous adenomatous polyps or CRC to determine the immunohistochemical expression levels of estrogen receptor (ER)-α, ER-β and the progesterone and androgen receptors (480 analyses). The ER-β expression levels differed between the groups: the group with FAP polyps had lower ER-β expression than that of the sporadic polyp group. With transformation of the sporadic polyps to cancer, there was a considerable decrease in ER-β expression (from 90% with strong expression to 80% with absent or weak expression) (p < 0.001). The ER-β expression was lower in T3/T4 tumors than in T1/T2 tumors (p = 0.015). The 5-year overall survival of CRC patients positively expressing ER-β exceeded that of patients without detectable expression levels (74.8% vs. 44.3%, respectively; p = 0.035). There was no significant expression of the androgen or progesterone receptor or ER-α among the groups. Differences in ER-β expression represent a potential mechanism through which estrogen might alter the susceptibility to colon cancer, thereby confirming the possibility of a protective role of estrogen against colorectal carcinogenesis.

Keywords

Colorectal cancer Survival Estrogen receptor Familial adenomatous polyposis Hormonal receptors Colorectal carcinogenesis 

Notes

Acknowledgments

We thank Dr. Renata Maymi Takahashi, Bruna Catin and Mariana Petaccia de Macedo, who was also a coworker in this study.

Compliance with Ethical Standards

Grants

This study was supported by grants from the State of São Paulo Research Foundation (FAPESP - 1453/10 - http://www.fapesp.br/en). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Gebert JF, Dupon C, Kadmon M, Hahn M, Herfarth C, von Knebel DM, Schackert HK (1999) Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli. Ann Surg 229:350–361. doi: 10.1097/00000658-199903000-00008 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Goss KH, Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 18:1967–1979. doi: 10.1200/JCO.2000.18.9.1967 CrossRefPubMedGoogle Scholar
  4. 4.
    Wong N, Lasko D, Rabelo R, Pinsky L, Gordon PH, Foulkes W (2001) Genetic counseling and interpretation of genetic tests in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Dis Colon rectum 44:271–279. doi: 10.1007/BF02234304
  5. 5.
    Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Järvinen H, Mecklin JP, Møller P, Myrhøi T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713. doi: 10.1136/gut.2007.136127 CrossRefPubMedGoogle Scholar
  6. 6.
    Nieuwenhuis MH, Vasen HF (2007) Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 61:153–161. doi: 10.1016/j.critrevonc.2006.07.004 CrossRefPubMedGoogle Scholar
  7. 7.
    Kennelly R, Kavanagh DO, Hogan AM, Winter DC (2008) Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9:385–391. doi: 10.1016/S1470-2045(08)70100-1 CrossRefPubMedGoogle Scholar
  8. 8.
    Giardiello FM, Hylind LM, Trimbath JD, Hamilton SR, Romans KE, Cruz-Correa M, Corretti MC, Offerhaus JA, Yang VW (2005) Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 128:1077–1080CrossRefPubMedGoogle Scholar
  9. 9.
    Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Investigators W's HI (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991–1004. doi: 10.1056/NEJMoa032071 CrossRefPubMedGoogle Scholar
  10. 10.
    Simon MS, Chlebowski RT, Wactawski-Wende J, Johnson KC, Muskovitz A, Kato I, Young A, Hubbell FA, Prentice RL (2012) Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 30:3983–3990. doi: 10.1200/JCO.2012.42.7732 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701–1712. doi: 10.1001/jama.291.14.1701 CrossRefPubMedGoogle Scholar
  12. 12.
    Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB (2009) Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 27:4542–4547. doi: 10.1200/JCO.2009.22.0764 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, Beral V (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 130:2387–2396. doi: 10.1002/ijc.26236 CrossRefPubMedGoogle Scholar
  14. 14.
    Lin KJ, Cheung WY, Lai JY, Giovannucci EL (2012) The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130:419–430. doi: 10.1002/ijc.26026 CrossRefPubMedGoogle Scholar
  15. 15.
    Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106:574–582. doi: 10.1016/S0002-9343(99)00063-7 CrossRefPubMedGoogle Scholar
  16. 16.
    Kouzmenko AP, Takeyama K, Kawasaki Y, Akiyama T, Kato S (2008) Ligand-dependent interaction between estrogen receptor alpha and adenomatous polyposis coli. Genes Cells 13:723–730. doi: 10.1111/j.1365-2443.2008.01200.x CrossRefPubMedGoogle Scholar
  17. 17.
    Dawson PM, Shousha S, Blair SD, Carter GD, Jones J, Alaghband-Zadeh J, Theodorou NA (1990) Oestrogen receptors in colorectal carcinoma. J Clin Pathol 43:149–151. doi: 10.1136/jcp.43.2.149 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hendrickse CW, Jones CE, Donovan IA, Neoptolemos JP, Baker PR (1993) Oestrogen and progesterone receptors in colorectal cancer and human colonic cancer cell lines. Br J Surg 80:636–640. doi: 10.1002/bjs.1800800531 CrossRefPubMedGoogle Scholar
  19. 19.
    Di Leo A, Messa C, Russo F, Misciagna G, Guerra V, Taveri R, Leo S (1994) Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci 39:2038–2042. doi: 10.1007/BF02088144 CrossRefPubMedGoogle Scholar
  20. 20.
    Meggouh F, Lointier P, Pezet D, Saez S (1991) Status of sex steroid hormone receptors in large bowel cancer. Cancer 67:1964–1970. doi: 10.1002/1097-0142(19910401)67:7<1964::AID-CNCR2820670724>3.0.CO;2-S CrossRefPubMedGoogle Scholar
  21. 21.
    Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD, Wolff R (2006) Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer 118:3140–3146. doi: 10.1002/ijc.21791 CrossRefPubMedGoogle Scholar
  22. 22.
    Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W (2005) Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomark Prev 14:2936–2942. doi: 10.1158/1055-9965.EPI-05-0514 CrossRefGoogle Scholar
  23. 23.
    Mostafaie N, Kállay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, Huber KR, Krugluger W (2009) Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog 48:642–647. doi: 10.1002/mc.20510 CrossRefPubMedGoogle Scholar
  24. 24.
    Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307. doi: 10.1007/s00428-010-0952-2 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW (2000) Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60:245–248PubMedGoogle Scholar
  26. 26.
    Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM (2007) Estrogen receptors α and β are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of min/+ mice. Cancer Res 67:2366–2372. doi: 10.1158/0008-5472.CAN-06-3026 CrossRefPubMedGoogle Scholar
  27. 27.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2009) American joint committee on cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  28. 28.
    Jassam N, Bell SM, Speirs V, Quirke P (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with dukes’ staging. Oncol Rep 14:17–21PubMedGoogle Scholar
  29. 29.
    Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39:1251–1258. doi: 10.1016/S0959-8049(03)00239-9 CrossRefPubMedGoogle Scholar
  30. 30.
    Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72:829–842. doi: 10.1016/j.steroids.2007.07.009 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kato S, Sato T, Watanabe T, Takemasa S, Masuhiro Y, Ohtake F, Matsumoto T (2005) Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother Pharmacol 56:4–9. doi: 10.1007/s00280-005-0102-8 CrossRefPubMedGoogle Scholar
  32. 32.
    Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, Kato S (2003) Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423:545–550. doi: 10.1038/nature01606 CrossRefPubMedGoogle Scholar
  33. 33.
    Métivier R, Reid G, Gannon F (2006) Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep 7:161–167. doi: 10.1038/sj.embor.7400626 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Björnström L, Sjöberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833–842. doi: 10.1210/me.2004-0486 CrossRefPubMedGoogle Scholar
  35. 35.
    Vasudevan N, Pfaff DW (2007) Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr Rev 28:1–19. doi: 10.1210/er.2005-0021 CrossRefPubMedGoogle Scholar
  36. 36.
    Nanda K, Bastian LA, Hasselblad V, Simel DL (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93:880–888. doi: 10.1016/S0029-7844(98)00424-4 PubMedCrossRefGoogle Scholar
  37. 37.
    Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, Schaffer D, Samowitz WS (2001) Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61:126–130PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Paulo Roberto Stevanato Filho
    • 1
    Email author
  • Samuel Aguiar Júnior
    • 1
  • Maria Dirlei Begnami
    • 2
  • Fábio de Oliveira Ferreira
    • 1
  • Wilson Toshihiko Nakagawa
    • 1
  • Ranyell Matheus Sobreira Batista Spencer
    • 1
  • Tiago Santoro Bezerra
    • 1
  • Philip Edward Boggiss
    • 1
  • Ademar Lopes
    • 1
  1. 1.Colorectal Tumor Nucleus of the Pelvic Surgery DepartmentA.C. Camargo Cancer CenterSão PauloBrazil
  2. 2.Department of PathologyA.C. Camargo Cancer CenterSão PauloBrazil

Personalised recommendations